Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBIO
CUSIPN/A
Phone617-945-7361
Debt
Debt-to-Equity Ratio-0.66
Current Ratio1.69
Quick Ratio1.69
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees61
Outstanding Shares45,140,000
Market Cap$262.73 million
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) announced its earnings results on Thursday, August, 9th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $3.64. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
3 brokers have issued 12-month price objectives for Translate Bio's stock. Their predictions range from $20.00 to $25.00. On average, they expect Translate Bio's share price to reach $23.00 in the next year. This suggests a possible upside of 304.2% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Adaptimmune Therapeutics (ADAP), Audentes Therapeutics (BOLD), Iovance Biotherapeutics (IOVA), Acorda Therapeutics (ACOR), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), Heska (HSKA), Novavax (NVAX), Avrobio (AVRO), Mesoblast (MESO), Scholar Rock (SRRK), Voyager Therapeutics (VYGR) and Vericel (VCEL).
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 49)
- Dr. Michael W. Heartlein, Chief Scientific Officer & CTO (Age 59)
- Mr. John R. Schroer CFA, CFO & Treasurer (Age 53)
- Mr. Paul D. Burgess J.D., Gen. Counsel (Age 45)
- Ms. Paula A. Cloghessy, Sr. VP of Human Resource (Age 47)
When did Translate Bio IPO?
(TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.
When does Translate Bio's lock-up period expire?
Translate Bio's lock-up period expires on Tuesday, December 25th. Translate Bio had issued 9,350,000 shares in its IPO on June 28th. The total size of the offering was $121,550,000 based on an initial share price of $13.00. After the expiration of Translate Bio's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $5.69.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $262.73 million. Translate Bio employs 61 workers across the globe.
What is Translate Bio's official website?
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
